1- Or 3-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2- ones: Potent, selective, and orally efficacious norepinephrine reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 18, 2009, Pages 5703-5711

  Zhang, Puwen ^a   Terefenko, Eugene A ^a   Bray, Jenifer ^a   Deecher, Darlene ^a   Fensome, Andrew ^a   Harrison, Jim ^a   Kim, Callain ^a   Koury, Elizabeth ^a   Mark, Lilly ^a   McComas, Casey C ^a   Mugford, Cheryl A ^a   Trybulski, Eugene J ^a   Vu, An T ^a   Whiteside, Garth T ^a   Mahaney, Paige E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 3 [1 (3 FLUOROPHENYL) 2 HYDROXY 3 METHYLAMINOPROPYL] 1,3 DIHYDROBENZIMIDAZOL 2 ONE; 1 ETHYL 3 [2 HYDROXY 3 (METHYLAMINO) 1 PHENYLPROPYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 FLUORO 3 [1 (3 FLUOROPHENYL) 2 HYDROXY 3 (METHYLAMINO)PROPYL] 1 ISOPROPYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 4 FLUORO 3 [2 HYDROXY 3 (METHYLAMINO) 1 PHENYLPROPYL] 1 ISOPROPYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; AMINE; ANALGESIC AGENT; ARYLOXYPROPANAMINE; ATOMOXETINE; BENZIMIDAZOLE DERIVATIVE; DESIPRAMINE; DOPAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; GABAPENTIN; MAZINDOL; MORPHINE; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HOT PLATE TEST; HUMAN; HYPERALGESIA; IC 50; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION; THERMOREGULATION;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; HYPERALGESIA; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPINAL NERVES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 70349220945     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900888c     Document Type: Article

References (62)

1. Gether, U.; Andersen, P. H.; Larsson, O. M.; Schousboe, A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 2006, 27, 375-383.
2. Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br. J. Pharmacol. 2006, 147, S82-S88.
3. Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin. Investig. Drugs 2007, 16, 1365-1377.
4. Liu, S.; Molino, B. F. Recent developments in monoamine reuptake inhibitors. Annu. Rep. Med. Chem. 2007, 42, 13-26.
5. Baldwin, D.; Buis, C.; Mayers, A. Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder. Expert Rev. Neurother. 2002, 2, 717-724.
6. Cipriani, A.; Furukawa, T. A.; Salanti, G.; Geddes, J. R.; Higgins, J. P. T.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I. M.; McGuire, H.; Tansella, M.; Barbui, C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373, 746-758.
7. Scates, A. C.; Doraiswamy, P. M. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. 2000, 34, 1302-1312.
8. Krell, H. V.; Leuchter, A. F.; Cook, I. A.; Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46, 379-384. (Pubitemid 46173196)
9. Christman, A. K.; Fermo, J. D.; Markowitz, J. S. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004, 24, 1020-1036.
10. Clauw, D. J.; Mease, P.; Palmer, R. H.; Gendreau, R. M.; Wang, Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin. Ther. 2008, 30, 1988-2004.
11. Nakagawa, A.; Watanabe, N.; Omori, I. M.; Barbui, C.; Cipriani, A.; McGuire, H.; Churchill, R.; Furukawa, T. A. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs 2008, 22, 587-602.
12. Pigott, T. A.; Prakash, A.; Arnold, L. M.; Aaronson, S. T.; Mallinckrodt, C. H.; Wohlreich, M. M. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr. Med. Res. Opin. 2007, 23, 1303-1318.
13. Russell, I. J.; Mease, P. J.; Smith, T. R.; Kajdasz, D. K.; Wohlreich, M. M.; Detke, M. J.; Walker, D. J.; Chappell, A. S.; Arnold, L. M. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136, 432-444.
14. Smith, T.; Nicholson, R. A. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc. Health Risk Manage. 2007, 3, 833-844.
15. Thor, K. B.; Kirby, M.; Viktrup, L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int. J. Clin. Pract. 2007, 61, 1349-1355.
16. Chen, C.; Dyck, B.; Fleck, B. A.; Foster, A. C.; Grey, J.; Jovic, F.; Mesleh, M.; Phan, K.; Tamiya, J.; Vickers, T.; Zhang, M. Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1346-1349.
17. Eildal Jonas, N. N.; Andersen, J.; Kristensen, A. S.; Jorgensen , A. M.; Bang-Andersen, B.; Jorgensen, M.; Stromgaard, K. From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J. Med. Chem. 2008, 51, 3045-3048.
18. Fish, P. V.; Ryckmans, T.; Stobie, A.; Wakenhut, F. [4-(Phenoxy)pyridin- 3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1795-1798.
19. Fish, P. V.; Barta, N. S.; Gray, D. L. F.; Ryckmans, T.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. Derivatives of (3S)-N-(biphenyl-2-ylmethyl) pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. Bioorg. Med. Chem. Lett. 2008, 18, 4355-4359.
20. Mahaney, P. E.; Gavrin, L. K.; Trybulski, E. J.; Stack, G. P.; Vu, A. T.; Cohn, S. T.; Ye, F.; Belardi, J. K.; Santilli, A. A.; Sabatucci, J. P.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Leventhal, L.; Koury, E. J.; Zhang, Y.; Mugford, C. A.; Ho, D. M.; Rosenzweig-Lipson, S. J.; Platt, B.; Smith, V. A.; Deecher, D. C. Structure-Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors. J. Med. Chem. 2008, 51, 4038-4049.
21. McComas, C. C.; Vu, A. T.; Mahaney, P. E.; Cohn, S. T.; Fensome, A.; Marella, M. A.; Nogle, L.; Trybulski, E. J.; Ye, F.; Zhang, P.; Alfinito, P.; Bray, J.; Johnston, G.; Koury, E.; Deecher, D. C. Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4929-4931.
22. Pontillo, J.; Wu, D.; Ching, B.; Hudson, S.; Genicot, M. J.; Gao, Y.; Ewing, T.; Fleck, B. A.; Gogas, K.; Aparicio, A.; Wang, H.; Wen, J.; Wade, W. S. Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics. Bioorg. Med. Chem. Lett. 2008, 18, 6151-6155.
23. Whitlock, G. A.; Blagg, J.; Fish, P. V. 1-(2-Phenoxyphenyl)-methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg. Med. Chem. Lett. 2008, 18, 596-599.
24. Whitlock, G. A.; Fish, P. V.; Fray, M. J.; Stobie, A.; Wakenhut, F. Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. Bioorg. Med. Chem. Lett. 2008, 18, 2896-2899.
25. Wu, D.; Pontillo, J.; Ching, B.; Hudson, S.; Gao, Y.; Fleck, B. A.; Gogas, K.; Wade, W. S. Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg. Med. Chem. Lett. 2008, 18, 4224-4227.
26. Zhang, M.; Jovic, F.; Vickers, T.; Dyck, B.; Tamiya, J.; Grey, J.; Tran, J. A.; Fleck, B. A.; Pick, R.; Foster, A. C.; Chen, C. Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3682-3686.
27. Zhang, P.; Terefenko, E. A.; McComas, C. C.; Mahaney, P. E.; Vu, A.; Trybulski, E.; Koury, E.; Johnston, G.; Bray, J.; Deecher, D. Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol- 2-ones as selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 6067-6070.
28. Zhou, J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 2004, 29, 1235-1244. (Pubitemid 40221722)
29. Kim, C. Y.; Trybulski, E. J.; Mahaney, P. E.; McConnell, O.; Zhang, Y.; Manas, E. S.; Ho, D.; Leiter, J.; Johnston, G. H.; Cosmi, S.; Deecher, D. C. Discovery of novel indolylphenylpropanolamine inhibitor of the norepinephrine transporter and its absolute stereochemistry. Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, Aug 17-21, 2008; American Chemical Society: Washington, DC, 2008, MEDI-179.
30. Katsuki, T.; Sharpless, K. B. The first practical method for asymmetric epoxidation. J. Am. Chem. Soc. 1980, 102, 5974-5976.
31. Melloni, P.; Carniel, G.; Della Torre, A.; Bonsignori, A.; Buonamici, M.; Pozzi, O.; Ricciardi, S.; Rossi, A. C. Potential antidepressant agents. alpha-Aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem. 1984, 19, 235-242.
32. For γ-hydroxyl propanamines, see Carlier, P. R.; Lo, M. M. C.; Lo, P. C. K.; Richelson, E.; Tatsumi, M.; Reynolds, I. J.; Sharma, T. A. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg. Med. Chem. Lett. 1998, 8, 487-492.
33. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb. J. Med. Chem. 2008, 51, 817-834.
34. Vu, A. T.; Cohn, S. T.; Terefenko, E. A.; Moore, W. J.; Zhang, P.; Mahaney, P. E.; Trybulski, E. J.; Goljer, I.; Dooley, R.; Bray, J. A.; Johnston, G. H.; Leiter, J.; Deecher, D. C. 3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 2464-2467.
35. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. J. Med. Chem. 2000, 43, 3714-3717.
36. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615-2623.
37. Riedel, W.; Dorward, P. K.; Korner, P. I. Central adrenoceptors modify hypothalamic thermoregulatory patterns of autonomic activity in conscious rabbits. J. Auton. Nerv. Syst. 1981, 3, 525-533.
38. Rintamaki, H.; Lahti, H.; Hissa, R. Feather position of the pigeon after intrahypothalamic injections of noradrenaline, 5-hydroxytryptamine and carbachol. Experientia 1981, 37, 1173-1175. (Pubitemid 12216551)
39. Deecher, D. C.; Alfinito, P. D.; Leventhal, L.; Cosmi, S.; Johnston, G. H.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007, 148, 1376-1383. (Pubitemid 46272809)
40. Loprinzi, C. L.; Kugler, J. W.; Sloan, J. A.; Mailliard, J. A.; LaVasseur, B. I.; Barton, D. L.; Novotny, P. J.; Dakhil, S. R.; Rodger, K.; Rummans, T. A.; Christensen, B. J. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356, 2059-2063.
41. Loprinzi, C. L.; Sloan, J. A.; Perez, E. A.; Quella, S. K.; Stella, P. J.; Mailliard, J. A.; Halyard, M. Y.; Pruthi, S.; Novotny, P. J.; Rummans, T. A. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 2002, 20, 1578-1583.
42. Maswood, N.; Cosmi, S.; Alfinito, P. D.; Leventhal, L.; Deecher, D. C. The role of the selective serotonin reuptake inhibitor fluoxetine in temperature regulation in ovariectomized rat models. Neuroendocrinology 2006, 84, 330-338.
43. Stearns, V.; Beebe, K. L.; Iyengar, M.; Dube, E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 2003, 289, 2827-2834. (Pubitemid 37430118)
44. Berendsen, H. H. G.; Weekers, A. H. J.; Kloosterboer, H. J. Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats. Eur. J. Pharmacol. 2001, 419, 47-54.
45. Sipe, K.; Leventhal, L.; Burroughs, K.; Cosmi, S.; Johnston, G. H.; Deecher, D. C. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res. 2004, 1028, 191-202.
46. Holden, J. E.; Schwartz, E. J.; Proudfit, H. K. Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha 1- and alpha 2-adrenoceptors. Neuroscience (Oxford) 1999, 91, 979-990.
47. Ren, K.; Ruda, M. A. Descendingmodulation of Fos expression after persistent peripheral inflammation. NeuroReport 1996, 7, 2186-2190. (Pubitemid 26361843)
48. Ren, K.; Dubner, R. Descending modulation in persistent pain: an update. Pain 2002, 100, 1-6. (Pubitemid 35305118)
49. Zhuo, M.; Gebhart, G. F. Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. Brain Res. 1991, 550, 35-48.
50. Collins, S. L.; Moore, R. A.; McQuay, H. J.; Wiffen, P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J. Pain Symptom Manage. 2000, 20, 449-458. (Pubitemid 30948740)
51. Sindrup, S. H.; Jensen, T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83, 389-400.
52. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharm. Exp. Ther. 1941, 72, 74-79.
53. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia, and catalepsy. Neuropharmacology 2005, 48, 658-672.
54. Kim, S. H.; Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50, 355-363.
55. Sullivan, N. R.; Leventhal, L.; Harrison, J.; Smith, V. A.; Cummons, T. A.; Spangler, T. B.; Sun, S.-C.; Lu, P.; Uveges, A. J.; Strassle, B. W.; Piesla, M. J.; Ramdass, R.; Barry, A.; Schantz, J.; Adams, W.; Whiteside, G. T.; Adedoyin, A.; Jones, P. G. Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-azabicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain. J. Pharmacol. Exp. Ther. 2007, 322, 1294-1304.
56. Olofson, R. A.; Vander Meer, R. K.; Hoskin, D. H.; Bernheim, M. Y.; Stournas, S.; Morrison, D. S. Synthesis, stability, structure, reactivity, and chemistry of N-alkylbenzoazetinones. J. Org. Chem. 1984, 49, 3367-3372.
57. Clark, R. L.; Pessolano, A. A. Synthesis of some substituted benzimidazolinones. J. Am. Chem. Soc. 1958, 80, 1657-1662.
58. Meanwell, N. A.; Sit, S. Y.; Gao, J.; Wong, H. S.; Gao, Q., St.; Laurent, D. R.; Balasubramanian, N. Regiospecific Functionalization of 1,3-Dihydro-2H-benzimidazol-2-one and Structurally Related Cyclic Urea Derivatives. J. Org. Chem. 1995, 60, 1565-1582.
59. Rossi, A.; Hunger, A.; Kebrle, J.; Hoffmann, K. Benzimidazole derivatives and related heterocycles. V. Condensation of o-phenylenediamine with aliphatic and alicyclic oxo esters. Helv. Chim. Acta 1960, 43, 1298-1313.
60. Singh, S.; Syme, C. A.; Singh, A. K.; Devor, D. C.; Bridges, R. J. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2001, 296, 600-611.
61. Hori, M.; Suzuki, K.; Yamamoto, T.; Nakajima, F.; Ozaki, A.; Ohtaka, H. Design and syntheses of a series of novel serotonin S3 antagonists. Chem. Pharm. Bull. 1993, 41, 1832-1841.
62. Tapia, I.; Alonso-Cires, L.; Lopez-Tudanca, P. L.; Mosquera, R.; Labeaga, L.; Innerarity, A.; Orjales, A. 2,3-Dihydro-2-oxo-1H-benzimidazole-1- carboxamides with Selective Affinity for the 5-HT4 Receptor: Synthesis and Structure-Affinity and Structure-Activity Relationships of a New Series of Partial Agonist and Antagonist Derivatives. J. Med. Chem. 1999, 42, 2870-2880.